文献速递膀胱癌与上尿路尿路上皮癌

组织学亚型/分化对根治性肾输尿管切除术后上尿路尿路上皮癌患者临床病理和肿瘤学结局的影响:一项综合更新的系统综述和荟萃分析

Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2025-04-11

结果显示HS/DD组患者更高比例具有≥pT3分期、高级别肿瘤、淋巴结侵犯、淋巴血管侵犯和接受辅助化疗,且癌症特异性生存、总生存和无复发生存显著更差,但膀胱内无复发生存和尿路上皮无复发生存两组相当。

要点

  • HS/DD与更晚期病理分期、高级别、淋巴结侵犯和淋巴血管侵犯相关。
  • HS/DD组癌症特异性生存、总生存和无复发生存显著更差。
  • HS/DD不预测更差的膀胱内无复发生存或尿路上皮无复发生存。

核心结论

  • UTUC伴HS/DD与更晚期/侵袭性特征相关,如更高的病理分期和分级、淋巴结侵犯和淋巴血管侵犯。
  • HS/DD与显著更差的癌症特异性生存、总生存和无复发生存相关,但不预测更差的膀胱内无复发生存或尿路上皮无复发生存。
  • 因此,检测到HS/DD应促使广泛治疗和更密切的随访。

研究设计与样本

  • 系统综述和荟萃分析,文献检索于2024年9月进行。
  • 主要结局为HS/DD组与纯尿路上皮癌(PUC)组之间临床病理特征和肿瘤学结局的差异。

主要发现

  • HS/DD存在于14%的肿瘤中。
  • 与PUC相比,HS/DD组≥pT3分期、高级别肿瘤、淋巴结侵犯(LNI)、淋巴血管侵犯(LVI)和接受辅助化疗的比例显著更高。
  • HS/DD组癌症特异性生存(CSS)显著更差(HR 1.65,95% CI 1.39-1.96)。
  • HS/DD组总生存(OS)显著更差(HR 1.84,95% CI 1.52-2.22)。
  • HS/DD组无复发生存(RFS)显著更差(HR 1.64,95% CI 1.43-1.87)。

关键数值与推荐

  • HS/DD组与PUC组相比,CSS的HR为1.65(95% CI 1.39-1.96)。
  • HS/DD组与PUC组相比,OS的HR为1.84(95% CI 1.52-2.22)。
  • HS/DD组与PUC组相比,RFS的HR为1.64(95% CI 1.43-1.87)。
  • 膀胱内RFS(IVRFS)和尿路上皮RFS(URFS)在两组间相当。

临床怎么用

  • HS/DD检测应促使更广泛的治疗和更密切的随访。
  • HS/DD与更差预后相关,需在临床决策中考虑。

局限性

  • 需要设计良好且具有中心病理审查的研究来提高推荐质量和患者护理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Upper tract urothelial carcinoma (UTUC) is associated with poor survival. Recent studies have evaluated whether the presence of histological subtypes or divergent differentiation (HS/DD) is associated with worse UTUC prognosis. Our aim was to assess the relationship between HS/DD and clinicopathological features and oncological outcomes for patients with UTUC undergoing radical nephroureterectomy (RNU) without investigating causal pathways. METHODS: A literature search was conducted in September 2024. Patients with UTUC who underwent RNU were included. The main outcomes were differences in clinicopathological features and oncological outcomes between HS/DD and pure urothelial carcinoma (PUC) groups. KEY FINDINGS AND LIMITATIONS: We included 22 studies involving 14 407 patients in our review. HS/DD was present in 14% of tumours. In comparison to PUC, the HS/DD group had significantly higher rates of ≥pT3 stage, high-grade tumours, lymph node invasion (LNI), lymphovascular invasion (LVI), and receipt of adjuvant chemotherapy. Pooled results revealed that the HS/DD group had significantly worse cancer-specific survival (CSS) (hazard ratio [HR] 1.65, 95% confidence interval CI] 1.39-1.96), overall survival (OS; HR 1.84, 95% CI 1.52-2.22) ,and recurrence-free survival (RFS; HR 1.64, 95% CI 1.43-1.87). Intravesical RFS (IVRFS) and urothelial RFS (URFS) were comparable between the groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings suggest that UTUC with HS/DD is associated with more advanced/aggressive features, such as higher pathological stage and grade, LNI, and LVI. HS/DD is associated with significantly worse CSS, OS, and RFS, but does not predict worse IVRFS or URFS. Therefore, HS/DD detection should prompt extensive treatment and closer follow-up. To improve the quality of recommendations and patient care, well-designed studies with central pathological review are needed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Krajewski W, Nowak Ł, Łaszkiewicz J, et al. Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis. Eur Urol Oncol. 2025. PMID: 40221279. doi:10.1016/j.euo.2025.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。